ECSP11011294A - Compuestos de anillo fusionados y su uso - Google Patents

Compuestos de anillo fusionados y su uso

Info

Publication number
ECSP11011294A
ECSP11011294A EC2011011294A ECSP11011294A ECSP11011294A EC SP11011294 A ECSP11011294 A EC SP11011294A EC 2011011294 A EC2011011294 A EC 2011011294A EC SP11011294 A ECSP11011294 A EC SP11011294A EC SP11011294 A ECSP11011294 A EC SP11011294A
Authority
EC
Ecuador
Prior art keywords
fusioned
ring compounds
diseases
angiotensin
hypertension
Prior art date
Application number
EC2011011294A
Other languages
English (en)
Inventor
Hideyuki Igawa
Tsuyoshi Maekawa
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of ECSP11011294A publication Critical patent/ECSP11011294A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se provee un nuevo compuesto representado por la siguiente fórmula en donde cada símbolo es como se definió en la memoria descriptiva o una de sus sales, que tiene una actividad antagonista del receptor de angiotensina II y una actividad agonista del receptor ? activado por el proliferador de peroxisomas y es de utilidad como un agente para la prevención o el tratamiento de enfermedades circulatorias tales como hipertensión, y similares y/o enfermedades metabólicas tales como diabetes, y similares, y otros.
EC2011011294A 2009-01-30 2011-08-30 Compuestos de anillo fusionados y su uso ECSP11011294A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2009020720 2009-01-30

Publications (1)

Publication Number Publication Date
ECSP11011294A true ECSP11011294A (es) 2011-09-30

Family

ID=42026435

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2011011294A ECSP11011294A (es) 2009-01-30 2011-08-30 Compuestos de anillo fusionados y su uso

Country Status (37)

Country Link
US (4) US8283353B2 (es)
EP (1) EP2384327B1 (es)
JP (2) JP4892649B1 (es)
KR (1) KR20110113758A (es)
CN (2) CN103788097B (es)
AR (1) AR075344A1 (es)
AU (1) AU2010208863A1 (es)
CA (1) CA2750710C (es)
CL (1) CL2011001848A1 (es)
CO (1) CO6362011A2 (es)
CR (1) CR20110463A (es)
CY (1) CY1114530T1 (es)
DK (1) DK2384327T3 (es)
DO (1) DOP2011000249A (es)
EA (1) EA019823B1 (es)
EC (1) ECSP11011294A (es)
ES (1) ES2433225T3 (es)
GE (1) GEP20135961B (es)
HK (1) HK1162505A1 (es)
HR (1) HRP20131017T1 (es)
IL (1) IL214283A0 (es)
MA (1) MA33071B1 (es)
ME (1) ME01621B (es)
MX (1) MX2011008058A (es)
MY (1) MY152946A (es)
NZ (1) NZ594606A (es)
PE (1) PE20120593A1 (es)
PL (1) PL2384327T3 (es)
PT (1) PT2384327E (es)
RS (1) RS53012B (es)
SG (1) SG173135A1 (es)
SI (1) SI2384327T1 (es)
TN (1) TN2011000368A1 (es)
TW (2) TWI468410B (es)
UY (1) UY32409A (es)
WO (1) WO2010087515A1 (es)
ZA (1) ZA201105867B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010208863A1 (en) * 2009-01-30 2011-09-08 Takeda Pharmaceutical Company Limited Fused ring compound and use thereof
ES2531465T3 (es) 2010-12-23 2015-03-16 Sanofi Derivados de pirimidinona, su preparación y su utilización farmacéutica
CZ304252B6 (cs) * 2011-04-11 2014-01-29 Zentiva, K. S. Způsob výroby 2-ethoxy-1-((2´-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)bifenyl-4-yl)methyl)-1H-benzo[d]imidazol-7-karboxylátů a jejich převedení na azilsartan
CA3027246A1 (en) 2016-06-20 2017-12-28 Novartis Ag Crystalline forms of triazolopyrimidine compound
EP3687293A1 (en) 2017-09-26 2020-08-05 Ecolab Usa Inc. Acidic/anionic antimicrobial and virucidal compositions and uses thereof
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
US11472791B2 (en) 2019-03-05 2022-10-18 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
WO2020223558A1 (en) 2019-05-01 2020-11-05 Incyte Corporation Tricyclic amine compounds as cdk2 inhibitors
CA3150681A1 (en) 2019-08-14 2021-02-18 Incyte Corporation Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
JOP20220087A1 (ar) 2019-10-11 2023-01-30 Incyte Corp أمينات ثنائية الحلقة كمثبطات لـ cdk2
CN112745319B (zh) * 2019-10-30 2022-06-17 中国科学院上海药物研究所 一类取代三环结构的化合物、其制备方法及用途
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5472967A (en) 1991-02-20 1995-12-05 Synthelabo 4-pyrimidinone derivatives their preparation and their application in therapy
FR2672892B1 (fr) * 1991-02-20 1994-01-14 Synthelabo Derives de 4-pyrimidinones, leur preparation et leur application en therapeutique.
TW251288B (es) * 1991-06-27 1995-07-11 Takeda Dharm Industry Co Ltd
IL102183A (en) 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd The heterocyclic compounds are converted into biphenyl groups, their production and the pharmaceutical compositions containing them
IT1250749B (it) * 1991-08-02 1995-04-21 Luso Farmaco Inst Composti eterociclici ad attivita' a ii antagonista
US5389632A (en) 1992-02-24 1995-02-14 Laboratoires Upsa Pyrazolopyrimidine derivatives which are angiotensin II receptor antagonists
FR2687677B1 (fr) * 1992-02-24 1996-10-11 Union Pharma Scient Appl Nouveaux derives de polyazaindenes antagonistes des recepteurs a l'angiotensine ii ; leurs procedes de preparation, compositions pharmaceutiques les contenant.
US5387747A (en) 1992-02-24 1995-02-07 Laboratoires Upsa Triazolopyrimidine derivatives which are angiotensin II receptor antagonists, their methods of preparation and pharmaceutical compositions in which they are present
IT1263804B (it) 1993-01-22 1996-09-03 Luso Farmaco Inst Derivati pirimidinonici fusi con eterocicli azotati ad attivita' a ii antagonista
GB9406573D0 (en) 1994-03-31 1994-05-25 Merck Sharp & Dohme Medicaments
AU6039296A (en) 1995-06-07 1996-12-30 G.D. Searle & Co. Method to treat cardiofibrosis with a combination therapy of an angiotensin ii antagonist and an epoxy-steroidal aldoste rone antagonist
AU6158096A (en) 1995-06-07 1996-12-30 G.D. Searle & Co. Spironolactone and angiotensin ii antagonist combination the rapy for treatment of congestive heart failure
DK0831910T3 (da) 1995-06-07 2002-05-21 Searle & Co Kombinationsterapi med epoxy-steroid aldosteronantagonist og angiotensin II-receptorantagonist til behandling af kongestivt hjertesvigt
AU5982296A (en) 1995-06-07 1996-12-30 G.D. Searle & Co. Method to treat cardiofibrosis with a combination of an angi otensin ii antagonist and spironolactone
FR2812876B1 (fr) 2000-08-08 2002-09-27 Galderma Res & Dev Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar-gamma et leur utilisation dans des compositions cosmetiques ou pharmaceutiques
SE0101579D0 (sv) 2001-05-04 2001-05-04 Astrazeneca Ab New compounds
US7232828B2 (en) 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
TW200418835A (en) 2003-01-24 2004-10-01 Tanabe Seiyaku Co A pyrazolopyrimidine compound and a process for preparing the same
US20050065184A1 (en) 2003-08-29 2005-03-24 Aaipharma Inc. Method of reducing the risk of oxidative stress
EP1730148A4 (en) * 2004-02-03 2009-08-19 Abbott Lab USE OF AMINOBENZOXAZOLES AS THERAPEUTIC AGENTS
RU2389731C2 (ru) 2004-06-02 2010-05-20 Такеда Фармасьютикал Компани Лимитед Конденсированное гетероциклическое соединение
US20050288272A1 (en) 2004-06-23 2005-12-29 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1 receptor antagonists
CA2579716A1 (en) 2004-06-23 2006-01-05 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and at1-receptor antagonists
CA2616150A1 (en) 2005-07-27 2007-02-01 Talia Weinstein Inhibition of the renin-angiotensin system for the treatment of renal, vascular and cartilage pathology
WO2007053406A1 (en) 2005-10-28 2007-05-10 Novartis Ag Combinations of antihypertensive and cholesterol lowering agents
WO2007051007A2 (en) 2005-10-28 2007-05-03 Novartis Ag Combination of antihypertensives with cholesterol-lowering agent
US20080064871A1 (en) 2006-05-26 2008-03-13 Japan Tobacco Inc. Production Method of Nitrogen-Containing Fused Ring Compounds
US20080132474A1 (en) 2006-11-09 2008-06-05 Gene Logic Inc. Breast cancer screening and treatment methods
US20090012052A1 (en) 2006-11-09 2009-01-08 Ore Pharmaceuticals Inc. Method for treating er+ breast cancer
BRPI0719060A2 (pt) * 2006-11-24 2014-02-04 Takeda Pharmaceutical Composto, prodroga, agente farmacêutico, métodos para inibir um receptor de angiotensina ii e/ou ativar um receptor ativado com proliferador de peroxisoma, e para prevenir ou tratar doenças ou condições, e, uso de um composto
JPWO2008143262A1 (ja) * 2007-05-21 2010-08-12 武田薬品工業株式会社 複素環化合物およびその用途
CN101888776B (zh) 2007-09-20 2015-03-11 罗切斯特大学 治疗或预防炎性病症的方法和组合物
PT2268612E (pt) 2008-03-24 2014-11-13 Novartis Ag Inibidores de metaloprotease de matriz à base de arilsulfonamidas
CA2723372A1 (en) 2008-05-05 2009-11-12 University Of Rochester Methods and compositions for the treatment or prevention of pathological cardiac remodeling and heart failure
AU2010208863A1 (en) 2009-01-30 2011-09-08 Takeda Pharmaceutical Company Limited Fused ring compound and use thereof

Also Published As

Publication number Publication date
US20140046056A1 (en) 2014-02-13
HK1162505A1 (en) 2012-08-31
CL2011001848A1 (es) 2012-02-03
US20110294832A1 (en) 2011-12-01
CN102369205B (zh) 2014-10-29
US8592431B2 (en) 2013-11-26
MY152946A (en) 2014-12-15
JP2011251970A (ja) 2011-12-15
EA019823B1 (ru) 2014-06-30
CO6362011A2 (es) 2012-01-20
GEP20135961B (en) 2013-11-11
MA33071B1 (fr) 2012-02-01
RS53012B (en) 2014-04-30
CA2750710A1 (en) 2010-08-05
JP4892649B1 (ja) 2012-03-07
IL214283A0 (en) 2011-09-27
PL2384327T3 (pl) 2013-12-31
CY1114530T1 (el) 2017-01-25
US20100197683A1 (en) 2010-08-05
DOP2011000249A (es) 2011-09-15
EP2384327A1 (en) 2011-11-09
EP2384327B1 (en) 2013-07-31
SI2384327T1 (sl) 2013-12-31
NZ594606A (en) 2013-06-28
CN102369205A (zh) 2012-03-07
AR075344A1 (es) 2011-03-23
US8921379B2 (en) 2014-12-30
DK2384327T3 (da) 2013-10-28
US8283353B2 (en) 2012-10-09
KR20110113758A (ko) 2011-10-18
US20110288087A1 (en) 2011-11-24
CA2750710C (en) 2018-09-04
MX2011008058A (es) 2011-09-01
JP5676379B2 (ja) 2015-02-25
WO2010087515A1 (en) 2010-08-05
ZA201105867B (en) 2012-10-31
JP2012513952A (ja) 2012-06-21
CN103788097B (zh) 2016-03-30
TW201031669A (en) 2010-09-01
HRP20131017T1 (hr) 2013-12-06
CR20110463A (es) 2011-12-01
UY32409A (es) 2010-08-31
EA201101138A1 (ru) 2012-04-30
US9115136B2 (en) 2015-08-25
CN103788097A (zh) 2014-05-14
TN2011000368A1 (en) 2013-03-27
SG173135A1 (en) 2011-08-29
PE20120593A1 (es) 2012-05-21
AU2010208863A1 (en) 2011-09-08
PT2384327E (pt) 2013-11-07
TW201444848A (zh) 2014-12-01
ES2433225T3 (es) 2013-12-10
ME01621B (me) 2014-09-20
TWI468410B (zh) 2015-01-11

Similar Documents

Publication Publication Date Title
ECSP11011294A (es) Compuestos de anillo fusionados y su uso
CL2012003053A1 (es) Combinacion farmaceutica que comprende un agonista del receptor glp-1 y linagliptin, inhibidor dpp-4; uso de la combinacion farmaceutica para el tratamiento de la diabetes tipo 2 y de la obesidad.
UY31863A (es) Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar
CL2011002697A1 (es) Compuestos derivados de 3-[4-(oxo-dihidropiridin)bencil]-1,3-oxazin-ona hidratados, inhibidores 11beta-hsd1; composicion farmaceutica que los comprende; y su uso en el tratamiento de la diabetes
CL2012000921A1 (es) Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes.
UY33379A (es) Compuestos de morfolina
CL2012001911A1 (es) Compuestos derivados de fumarato; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad inflamatoria o neurodegenerativa.
CL2009000316A1 (es) Compuestos derivados de urea de benzomorfanos y sus sales, inhibidores de la enzima 11-beta-hidroxiesteroide deshidrogenasa; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de trastornos metabolicos.
CL2012002944A1 (es) Compuestos derivados de amino-pirimidinas; composiciones farmacéuticas que los comprenden; y su uso para el tratamiento de una enfermedad afección seleccionada de trastornos neuromusculares, esclerosis lateral amiotrófica, miastenia grave, entre otras.
CL2012002945A1 (es) Compuestos derivados de amino-piridazinas; composiciones farmacéuticas que los comprenden; y su uso para el tratamiento de una enfermedad afección seleccionada de trastornos neuromusculares, esclerosis lateral amiotrófica, miastenia grave, entre otras.
CL2013002053A1 (es) Compuestos derivados de heterociclicos, antagonistas del receptor de glucagon; composicion farmaceutica que lo comprende y su uso en el tratamiento de diabetes y enfermedades metabolicas. pct
MY155317A (en) Benzene sulfonamide thiazole and oxazole compounds
CL2008000418A1 (es) Uso de un antagonista de la il-23 para el tratamiento de una infeccion fungica.
CL2009000873A1 (es) Compuestos derivados de ciclohepta[b]piridina, antagonistas del receptor de cgrp; composicion farmaceutica; y uso para el tratamiento de la migrana.b
GT201700023A (es) Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
CL2007002890A1 (es) Compuestos derivados de 2-piridincarboxamida, activador de glucosinasa; composicion farmaceutica; y uso del compuesto para el tratamiento de diabetes o la obesidad.
CL2013003686A1 (es) Compuestos derivados de ergolina, antagonista del receptor de 5-ht1d; útiles para el tratamiento de la migraña.
CL2008002708A1 (es) Compuestos derivados de azaciclilisoquinolinona e isoindolinona, antagonistas de histamina-3; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuestos; y uso del compuesto para el tratamiento de un trastorno cognitivo,
CL2009000004A1 (es) Forma cristalina de r-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida; composicion farmaceutica que comprende a dicha forma cristalina; y uso para el tratamiento de diabetes o hiperglicemia.
CO6260091A2 (es) Derivados de iminopiridina y su uso
DOP2013000236A (es) Inhibidores de la poli(adp-ribosa)polimerasa(parp) para el tratamiento de la neuropatia periferica inducida por quimioterapia (cipn)
CL2011003154A1 (es) Compuestos derivados de pirazinooxazepina, activador del receptor de serotonina 5-ht2c, composicion farmaceutica que los comprende; y su uso en el tratamiento y/o profilaxis de sintomas del aparato urinario inferior, obesidad y/o prolapso de organos.
CL2012001290A1 (es) Compuestos derivados de canfenos arilados, estimulantes selectivos de receptores cb2; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad, trastorno o afeccion seleccionada de inflamacion, dolor, alergia, diabetes, ateroesclerosis, artritis y emesis, entre otras.
NI201000051A (es) Benzotiazoles como moduladores del receptor de grelina.
ECSP10010379A (es) Derivados de oxindol sustituido y su uso para el tratamiento de enfermedades dependientes de la vasopresina